Ascentage Pharma Group Stock Target Price
| AAPG Stock | 26.37 0.13 0.50% |
Fundamental analysis of Ascentage Pharma allows traders to better anticipate movements in Ascentage Pharma's stock price by examining its financial health and performance throughout various phases of its business cycle.
Ascentage | Target Price | Build AI portfolio with Ascentage Stock |
Ascentage Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ascentage Pharma's direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ascentage Pharma could also be used in its relative valuation, which is a method of valuing Ascentage Pharma by comparing valuation metrics of similar companies.Ascentage Pharma is currently under evaluation in target price category among its peers.
Ascentage Pharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of Ascentage Pharma from analyzing Ascentage Pharma's financial statements. These drivers represent accounts that assess Ascentage Pharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Ascentage Pharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 7.0B | 7.9B | 8.7B | 38.3B | 34.5B | 36.2B | |
| Enterprise Value | 6.4B | 8.2B | 9.4B | 38.7B | 34.9B | 36.6B |
Ascentage Fundamentals
| Return On Equity | -1.6 | ||||
| Return On Asset | -0.23 | ||||
| Profit Margin | (2.97) % | ||||
| Operating Margin | (2.37) % | ||||
| Current Valuation | 2.52 B | ||||
| Shares Outstanding | 92.96 M | ||||
| Shares Owned By Institutions | 0.09 % | ||||
| Number Of Shares Shorted | 254 | ||||
| Price To Book | 25.63 X | ||||
| Price To Sales | 6.28 X | ||||
| Revenue | 980.65 M | ||||
| Gross Profit | 354.93 M | ||||
| EBITDA | (237.63 M) | ||||
| Net Income | (395.25 M) | ||||
| Total Debt | 1.67 B | ||||
| Book Value Per Share | 0.28 X | ||||
| Cash Flow From Operations | (111.36 M) | ||||
| Short Ratio | 0.06 X | ||||
| Earnings Per Share | (2.08) X | ||||
| Target Price | 45.71 | ||||
| Number Of Employees | 605 | ||||
| Beta | 1.11 | ||||
| Market Capitalization | 2.45 B | ||||
| Total Asset | 2.62 B | ||||
| Retained Earnings | (5.77 B) | ||||
| Working Capital | 307.55 M | ||||
| Net Asset | 2.62 B |
About Ascentage Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ascentage Pharma Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ascentage Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ascentage Pharma Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Ascentage Pharma is a strong investment it is important to analyze Ascentage Pharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ascentage Pharma's future performance. For an informed investment choice regarding Ascentage Stock, refer to the following important reports:Check out Ascentage Pharma Piotroski F Score and Ascentage Pharma Altman Z Score analysis. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ascentage Pharma. If investors know Ascentage will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ascentage Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share | Quarterly Revenue Growth (0.72) | Return On Assets | Return On Equity |
The market value of Ascentage Pharma is measured differently than its book value, which is the value of Ascentage that is recorded on the company's balance sheet. Investors also form their own opinion of Ascentage Pharma's value that differs from its market value or its book value, called intrinsic value, which is Ascentage Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ascentage Pharma's market value can be influenced by many factors that don't directly affect Ascentage Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ascentage Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ascentage Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ascentage Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.